Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(14%)
Results Posted
40%(2 trials)

Phase Distribution

Ph phase_1
1
14%
Ph phase_4
4
57%
Ph early_phase_1
1
14%

Phase Distribution

2

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
1(16.7%)
Phase 4Post-market surveillance
4(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(5)

Detailed Status

Completed5
Enrolling by invitation1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (16.7%)
Phase 11 (16.7%)
Phase 44 (66.7%)

Trials by Status

completed571%
enrolling_by_invitation114%
active_not_recruiting114%

Recent Activity

1 active trials
Showing 5 of 7
enrolling_by_invitationphase_4

A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine

NCT07545564
completedearly_phase_1

Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)

NCT04901455
completedphase_1

Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection

NCT02597647
active_not_recruitingphase_4

Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine

NCT07232745
completedphase_4

Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents

NCT02250274
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07545564Phase 4

A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine

Enrolling By Invitation
NCT04901455Early Phase 1

Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT02597647Phase 1

Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection

Completed
NCT07232745Phase 4

Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine

Active Not Recruiting
NCT02250274Phase 4

Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents

Completed
NCT02019745

Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers

Completed
NCT03022435Phase 4

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7